CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 57 enrolled
Drug / intervention
carmoterol (CHF 4226) +3 moredrug
Likely dose
carmoterol (CHF 4226) 2 μgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00640484
NCT00640484Phase 2Completed
CompareCT.gov

Evaluation of the Effect of 2 Weeks Treatment With CHF 4226 pMDI 2µg and 4µg, Given Once Daily in the Morning, on 24-Hour FEV1 in Patients With COPD

Chiesi Farmaceutici S.p.A.·interventional·Posted Mar 21, 2008·Updated Aug 27, 2010

In Brief

A Phase 2 clinical trial evaluating carmoterol (CHF 4226), placebo, and 1 other intervention for Chronic Obstructive Pulmonary Disease. Completed, enrolled 57 participants across 15 sites.

Detailed Summary

The purpose of this study is to confirm the dose of CHF 4226 (carmoterol) that should be given once a day to patients with COPD in order for the effect to last for 24 hours.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsChronic Obstructive Pulmonary Disease
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedMar 21, 2008
Enrollment StartApr 1, 2008
Primary CompletionOct 1, 2008
TodayJul 2, 2026
Enrollment to primary: 6 monthsPosted 18.3 years ago

Interventions

carmoterol (CHF 4226)drug

carmoterol (CHF 4226) 2 μg once a day, in the morning (1 puff of carmoterol 2 μg + 1 puff of placebo pMDI)

carmoterol (CHF 4226)drug

carmoterol (CHF 4226) 4 μg once a day, in the morning (1 puff of carmoterol 2 µg + 1 puff of carmoterol 2µg)

placebodrug

placebo once a day, in the morning (1 puff of placebo pMDI + 1 puff of placebo pMDI)

salmeteroldrug

Salmeterol 50 μg twice daily, in the morning and in the evening (1 blister of Serevent Diskus BID)